about
Integrating lifestyle approaches into osteoarthritis careWhy regenerative stem cell medicine progresses slower than expectedDesigning phase II trials in cancer: a systematic review and guidance.Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in ratsAntitumoral materials with regenerative function obtained using a layer-by-layer techniqueTesting for efficacy in adaptive clinical trials with enrichmentMedicinal chemistry for 2020"Quantum Leap" in Photobiomodulation Therapy Ushers in a New Generation of Light-Based Treatments for Cancer and Other Complex Diseases: Perspective and Mini-Review.Ethical issues for control-arm patients after revelation of benefits of experimental therapy: a framework modeled in neuroblastomaConcordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder.Pluripotent human stem cells: A novel tool in drug discovery.Molecular networks in drug discovery.Deleterious effects of reactive metabolites.A review of advanced small-scale parallel bioreactor technology for accelerated process development: current state and future need.A retrospective study of amitriptyline in youth with autism spectrum disorders.'Reference composition' not 'lead compound': recent developments in case law for obviousness of pharmaceutical composition claims.Applications for oncologic drugs: a descriptive analysis of the oncologic drugs advisory committee reviews.A randomized, double-blind comparison shows the addition of oxygenated glycerol triesters to topical mentholated cream for the treatment of acute musculoskeletal pain demonstrates incremental benefit over time.The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009.Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets.
P2860
Q26781937-F3ED99C3-170C-4D09-92D6-818CF95D50E9Q28245006-86037DFF-5320-4A27-AB50-5D238C550F64Q33945307-3CCCCCD8-D99C-4D1B-B2C7-C791BC165300Q34193514-70E17F09-2B5F-4753-B0FC-2525B355AB78Q34596727-079C112C-B914-4733-9E4E-11762D0F1E12Q35161657-FA0B4B8D-04F3-41C0-A23F-D081C683F414Q35185239-53EA876A-973C-473A-B088-E161F1451297Q35593223-BB780B1E-AF55-4CBE-9F2C-30FBAFB9FDD4Q35927313-55C131E4-64EF-4B0E-9E29-9CA47CD2C593Q36589638-F8D749E3-3AE9-4B6E-8B2A-2A82F7985251Q36914736-DAE62F43-732C-4640-82F3-759B94512F31Q37701837-36586094-BE95-4D50-9AD0-B61E5019AFD1Q37798843-DF160412-00AF-4EC0-BC49-713C0A1224D6Q37802740-D815ABB8-DD35-4A1B-98E6-6CC8BD83792FQ37839908-D7FBE125-D6C2-4500-9868-7594F39EEE88Q38058418-0075BAB1-3C2E-445E-A239-76DFBB1171D3Q38162933-82590F35-D6D0-4DD1-960B-7A6DA9CE5259Q38193714-0E532C68-AE3C-401D-8C8C-4B54FE63642DQ39252392-70B0CBA8-2647-492C-ACD6-913CA695177AQ40858515-37596393-1B73-4575-BB53-AECA59ABDE9FQ45735814-B538367C-D86C-48DC-A3D0-FC3548219927Q50865512-53859D32-A070-45EA-96D0-958A00AB64FF
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Drug development cost estimates hard to swallow
@ast
Drug development cost estimates hard to swallow
@en
Drug development cost estimates hard to swallow
@nl
type
label
Drug development cost estimates hard to swallow
@ast
Drug development cost estimates hard to swallow
@en
Drug development cost estimates hard to swallow
@nl
prefLabel
Drug development cost estimates hard to swallow
@ast
Drug development cost estimates hard to swallow
@en
Drug development cost estimates hard to swallow
@nl
P356
P1476
Drug development cost estimates hard to swallow
@en
P2093
Roger Collier
P304
P356
10.1503/CMAJ.082040
P407
P577
2009-02-03T00:00:00Z